Nuovo Biologics, LLC

Our Team

Core key skilled partners disciplined in Biomedical Sciences, Pharmaceutical Production, Basic Research, Clinical Study Management, Business Management & Finance

Our Management Team

Jay E. Yourist, Ph.D.

President and Chief Executive Officer

Dr. Yourist, who you will meet again in our Scientist section, is the Nuovo Biologic's President and Chief Executive Officer with overall responsibility for not only the clinical and laboratory operations, but also the day to day direction and management of Nuovo Biologics.

Dr. Yourist brings management experience in both the private and public sectors. Dr. Yourist was a Founder and CEO of CRP Network, LLC performing clinical research for the Pharma industry. Previously to his leadership of CRP Network, Dr. Yourist was a gubernatorial appointee serving as the Director of the Division of Vocational Rehabilitation and the Social Security Office of Disability Determination for the State of Florida. There he was also responsible to manage the State's innovative Head and Spinal Cord Injury Programs.

Stuart P. Rose

Vice President for Business Development

Stuart Rose holds a Bachelor's degree in Business Administration from the University of Miami and has over forty years of involvement in federal, state and local government. After graduation and roles at the Florida Attorney General's office, and later for Miami-Dade County Mayor Steve Clark, Mr. Rose was a founding partner in Project Masters, a full service Public Relations firm specializing in political campaigns, governmental relations and special event planning. There, he and his partners made a reputation for successfully guiding a series of high profile election victories for local, state and congressional office holders. For nearly two decades, Project Masters provided its clients with campaign victories, project victories and sound advice along the way.

Following his years at Project Masters, Mr. Rose focused on strategic planning and relationship marketing for large companies and organizations.  His firm offered its clients access to those "decision makers" who were vital to their projects' success. From contact to completion, he assisted his clients in navigating the often-complex processes of both government and "Network Marketing."  His decision maker network strategies were proven successful.

Over the years, Mr. Rose has participated in projects and regularly serviced clients with interest in such diverse fields as health care, aviation support services, solid waste, engineering, technology, communications and security, to mention a few.

Jonathan Gat

Director of Clinical Studies

Jonathan Gat is the Clinical Research Director of Nuovo Biologics since May 2011. Prior to Nuovo Biologics, he served as the Operations Manager for Skilled Health Systems, where he managed both clinical trials and clinical research programs. Mr. Gat is an experience operations and project manager. He studied International Business at both the London School of Economics and the University of Brussels where he earned his Masters of Business Administration.

Mr. Gat's broader career accomplishments include working early stage businesses in financial investing, clinical research, and online sales. Leadership and management roles include serving as Business Development Manager for Awesome Avenue, an online clothing store, and Founder and Partner at Prague Street Advisers, and Operations Director for DebtAuction.com. A good organizer, Mr. Gat specializes in developing and streamlining business processes and workflow.

Prior to these experiences, Mr. Gat gained extensive trade and government experience via his roles at the American Israel Chamber of Commerce, the Israel Government Trade Office, and the State of California Insurance Commissioner's office. These roles prepared Mr. Gat for a successful career navigating political and highly regulated industries. Mr. Gat also serves on the City of Los Angeles Workforce Investment Board.

Anthony LaVecchia

Director of Operations

Anthony LaVecchia received his Bachelor of Science degree in Chemistry from the Florida International University in Miami. After graduation, he worked for 15 years for Coulter Corporation (Beckman Coulter Inc.) starting as a Chemical Safety Coordinator, then moving through research and development in the Analytical Chemistry and Radio-Chemistry departments, where he was responsible for radioisotope tagging of the CD20 marker for non-Hodgkin’s lymphoma and optimizing the analytical release assays for the drug. Anthony was promoted to Senior Scientist in Retrovirology Manufacturing Technical Operations for the FDA Licensed HIV-1 p24 Antigen Assay, where he worked for the last 10 years of his employment with Beckman Coulter.

Anthony moved on to Goodwin Biotech, a biologics contract manufacturing organization, as the Supervisor of Analytical Quality Control. Anthony’s responsibilities included overseeing the release of multiple cGMP manufactured vaccines as well as several oncology products for FDA Phase I, II and III Human Clinical Trials.

Anthony next managed a research and development laboratory as Senior Scientist for a medical diagnostic company, Health Chem Diagnostics LLC. During his four years at Health Chem, Anthony’s work primarily involved improving a transdermal glucose detection meter for diabetics. Other responsibilities included submitting IRB’s for in house clinical trials and acting as sub-investigator for the clinical studies and preparing the device for clinical trials in the European Union. While at Health-Chem, Anthony was responsible for various other medical devices such as lateral flow assays for cholesterol, nitrites in urine and malaria.

In 2012, Anthony started his own consulting firm, APL Scientific Consulting Inc., which enabled him to take a contract position at Nuovo Biologics. Once on board, he realized the potential of the product line at Nuovo and quickly purchased stock in the company, becoming an owner. After starting out in the R & D department, he now is the Director of Operations for Nuovo, implementing FDA regulations that will bring the facility to the cGLP and eventually cGMP status. Some of his responsibilities at Nuovo Biologics include writing CMC for FDA submission, oversight of facility compliance, manufacture of product for use in pilot studies, working with Research and Development to find innovative ways to improve our manufacturing process and pinpoint the mechanism of action for our product. Anthony hopes to use his 22 years of technical experience to support the company and help propel Nuovo Biologics to earn several FDA labels in both the animal and human space.